newsletter masthead
March 22, 2018
Vogelbaum and Shah Named Crain's Physician Innovators
Drs. Michael Vogelbaum and Chirag Shah were recently named Physician Innovators by Crain's Cleveland Business. Physician Innovators were nominated by their peers for their commitment to innovation and excellence - both toward their patients and the Northeast Ohio community. 

Michael Vogelbaum Dr. Vogelbaum is Associate Director for the Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic, member of the Case Comprehensive Cancer Center,  and Professor of Neurological Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. 

Dr. Shah is Director of Clinical Research in the Department of Radiation Oncology at the Cleveland Clinic, member of the Case Comprehensive Cancer Center, and Associate Professor of Medicine at  the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. 
Case CCC Featured on Cover of JNCCN
JNCCN-cover-2018 The Case Comprehensive Cancer Center, UH Seidman Cancer Center, and Cleveland Clinic Taussig Cancer Institute are featured on the cover of the March issue of JNCCN

Case Gastrointestinal Cancers SPORE Retreat
May 18, 2018 | Tinkham Veale University Center 

Registration is open for the Case GI Cancers SPORE Annual Retreat. 

Agenda Topics Include: 
  • Colon Cancer
  • Barrett's Esophagus
  • Cancer Metastasis
  • Cancer Prevention
  • Cancer in Minorities
Call for Abstracts
All trainees and fellows are invited to submit poster abstracts to Dr. John Wang ( by May 1, 2018. 

Cash prize will be awarded for Best Poster! 
This is your last chance to register to attend the 2nd Annual Cancer Disparities Symposium: Taking it to the Streets: Where Cancer Disparities Research and Community Intersect, this  Friday, March 23, 2018 at the Wolstein Research Building
2018 symposium highlights: 
  • Participants are eligible to receive 6 Continuing Research Education Credits (CRECs)
  • Keynote presentations from leading cancer disparities researcher, Lucile L. Adams-Campbell, PhD, from the Georgetown University Lombardi Comprehensive Cancer Center, and Francis Frances Mills, MA OCPSII, Director of the Cleveland Office of Minority Health
  • Poster session highlighting academic research and community programs
  • Networking session
  • All attendee forum 
  • Details of the 2018 Pilot Grant Program for Cancer Disparities Research will be discussed 
There is no cost to attend, but we do ask that you pre-register

CSC 2018 - web banner
Cancer Stem Cell Conference (CSC 2018), hosted by the Case Comprehensive Cancer Center and National Center for Regenerative Medicine, is designed to bring together individuals working in the field of cancer stem cell research. CSC 2018 will feature renowned keynote speakers and leaders in the field. This conference is guaranteed to have cutting edge research from a variety of niches within the field.  Join us August 6-8, 2018 at the Tinkham Veale University Center on CWRU campus! 

Call for Abstracts
The Cancer Stem Cell conference will feature oral and poster presentations selected from submitted abstracts. 
All trainees and faculty conducting related research to the topic area are invited to submit abstracts.

To be considered for the Young Investigator Award, abstract submission should also be accompanied by a CV and a letter of support from a current or previous mentor, or colleague. This award is open to senior trainees or junior faculty (less than 5 years from their first independent position).

Abstract submission deadline is Tuesday, May 15 at 5pm to

DNA Repair Symp Banner The Case Comprehensive Cancer Center and Case Western Reserve University will host the 20th Annual Midwest DNA Repair Symposium May 5-6, 2018 . This symposium is a great opportunity for people working on DNA damage and repair in the midwest area to gather together and discuss science! The agenda promises exciting science and opportunities for networking, poster presentations, and keynote presentations from field experts  Stephen Kowalczykowski and Lee Zou

Call for Abstracts
The 20th Annual Midwest DNA Repair Symposium will feature oral and poster presentations.  All graduate students, postdocs, research technician, faculty and fellows conducting related research are invited to submit abstracts. Monetary Prizes will be awarded.

**Abstract submission deadline is Monday, April 2 at 5pm to** 
Pilot Project Grants: American Cancer Society IRG Awards
Letter of Intent Deadline: Apr 2, 2018
Application Deadline: Apr 16, 2018
  • ACS logo Pilot funding for CANCER-RELATED research in basic, clinical, prevention & control, behavioral, health services and epidemiology.
  • Up to $30,000 award.
  • Applications accepted for general cancer-related projects and for special interest projects in adolescent-and-young-adult cancer research.
IRG pilot project grants are intended to support independent, self-directed investigators early in their careers (usually assistant professor or equivalent). Applicants for the pilot project grants should be within 6 years of their first independent research or faculty appointment and eligible to apply for an independent national competitive research grant, but do not currently hold such a cancer-related grant. 

Visit for more information.
Pilot Projects from VeloSano Bike to Cure
Deadline Extended: Apr 10, 2018
With the generous support from VeloSano Bike to Cure 2017, the Case Comprehensive Cancer Center is providing seed funding for highly innovative and impactful proposals that will generate key data for larger, nationally competitive grants. Projects aligned with at least one of six new Research Initiatives (Cancer Genomics, Cancer Immunotherapy, Brain Tumors, Drug Discovery and Development, Women's Cancers, Community Outreach and Cancer Health Disparities) and the Center's Strategic Plan are preferred. Collaborative, multi-investigator projects are particularly encouraged.
Limited Submission: 2018 V Foundation Translational Cancer Research Grant
Internal Deadline: March 24, 2018 at 5p ET
Nomination Deadline: April 16, 2018 at 5p ET
Application Deadline: May 30, 2018 at 5p ET
V Foundation logo The Case Comprehensive Cancer Center is invited to submit ONE nominee for consideration for the  2018 V Foundation Translational Cancer Research Grant.

The V Foundation for Cancer Research seeks to support translational research projects within the scope of all types of cancers. The Translational Research Award is a $600,000 grant awarded in three annual installments of $200,000. Indirect costs up to a maximum of 10% within the total award are permitted.

To be considered for the nomination, submit a one-page LOI and biosketch to  by March 24, 2018 . 
A River Runs Through the Life of a Leukemia Specialist
ASCO Post - Mar 10, 2018
For this installment in the Living a Full Life series, 
Matt Kalaycio, MD, of the Cleveland Clinic, was interviewed by Guest Editor Jame Abraham, MD, FACP, both of the Case Comprehensive Cancer Center. Dr. Kalaycio is Chairman, Department of Hematologic Oncology Blood Disorders at the Cleveland Clinic, where he is also Director of the Bone Marrow Transplant Program and Myeloma Program.
Swallowable Test Developed for Barrett's Esophagus
Helio/HemOnc Today - Mar 21, 2018
An encapsulated balloon device combined with methylated DNA biomarkers demonstrated sensitivity and specificity higher than 90% for the detection of Barrett's esophagus, a precursor to esophageal cancer.
Sanford Markowitz, MD, PhD, Markowitz-Ingalls professor of cancer genetics at Case Western Reserve University School of Medicine and co-leader of the GI Cancer Genetics Program at Case Comprehensive Cancer Center, and colleagues performed genome-wide screening and identified high-frequency DNA methylation within the CCNA1 and VIM loci.
Pacritinib Reduces Splenomegaly, Symptoms in Myelofibrosis
HemOnc Today - Mar 19, 2018
Ruxolitinib (Jakafi, Incyte), a JAK1/JAK2 inhibitor, is the only FDA-approved treatment for myelofibrosis.  "Ruxolitinib has been a touchstone for treating the disease, but it has its drawbacks," Aaron T. Gerds, MD , Case Comprehensive Cancer Center, assistant professor of medicine at Cleveland Clinic and a HemOnc Today Next Gen Innovator, told HemOnc Today. "It doesn't work for everyone forever. A patient's disease will eventually progress at some point, whether it's in symptoms, spleen size or to a more accelerated phase. Also, there are limitations with cytopenias."
Can Technology Help Predict Lung Cancer Prognosis? - Mar 19, 2018
Dr. Vamsidhar Velcheti, Case Comprehensive Cancer Center, thoracic oncologist at the Cleveland Clinic, recently earned a $3 million grant from the National Cancer Institute to complete a clinical trial using similar predictive analysis techniques to determine which patients are most likely to benefit from chemotherapy. The trial is based on a study Velcheti and his team conducted in collaboration with Case Western Reserve University in Cleveland. 
ideastream - Mar 14, 2018
Colorectal is the second deadliest cancer in the United States and affects both men and women. Although the disease is more commonly diagnosed in seniors, it can also strike young adults as well. ideastream's Rick Jackson spoke with Dr. Dale Shepard, Case Comprehensive Cancer Center, an oncologist at the Cleveland Clinic, to learn the potential warning signs of colorectal cancer, tips for speaking with physicians about concerns, and how often people should be screened for the disease. 
Phase 3 Trial of Idera's IMO-2125 Combo Therapy Is Recruiting Advanced Melanoma Patients
Immuno-Oncology News - Mar 12, 2018
"For our advanced melanoma patients who have not benefited from anti-PD-1 therapy and in BRAF mutant melanoma, BRAF targeted therapy, there are very few, limited options available today," said Ahmad Tarhini, MD, Case Comprehensive Cancer Center, director of the Melanoma and Skin Cancer Program at Cleveland Clinic Taussig Cancer Institute.
NIH BULLETIN- Notices and Funding Opportunities
Notice of NCI's participation on PA-18-498, End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)(NOT-CA-18-032)

Notice of NCI's participation on PA-18-499, End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)(NOT-CA-18-033)

Notice of Change to PAR-17-233 "Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01)"(NOT-CA-18-055)

Notice of Correction to the Specific Research Objectives for PA-16-175 Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)"(NOT-CA-18-057)

Revision: Notice of Correction to Application Instructions in RFA-HL-19-008: Limited Competition: Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) (U01 Clinical Trial Not Allowed)(NOT-HL-18-609)

Program Announcements
Mechanisms of Alcohol-associated Cancers (R01)(PA-17-220)
Deadline: Standard dates apply

Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01)(PAR-17-233)
Deadline: Standard dates apply

Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01)(PAR-16-049)
Deadline: Nov 17, 2018

Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional)(PAR-18-717)
Fri, Mar 23
Second Annual Cancer Disparities Symposium: Taking it to the Streets: Where Cancer Disparities Research and Community Intersect
7:30a-3p WRB 1-413

Hematology and Oncology Grand Rounds
Ehsan Malek, MD Instructor, Hematology and Oncology, University Hospitals 
"TGF-β: An Emerging therapeutic target in multiple myeloma"
8:30a Wearn 137

TCI Grand Rounds
8a CA5-120
Mon, Mar 26
Pathology Research Seminar Series
Sarah Taylor
Narla Lab, CWRU
"Defining the role of endometrial cancer PP2A A-alpha mutations in tumorigenesis"
12p WRB 1-413
Tues, Mar 27
Immunology Research Seminar
Mark Shlomchik, MD, PhD
University of Pittsburgh
"Signaling and selection in germinal center B cells"
12p WRB 1-413

THOR Seminar
Farhad Ravandi, MD
Chief, Developmental Therapeutics, University of Texas, MD Anderson Cancer Center
1p NE1-205
Thurs, Mar 29
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology Seminar
Angelica Cruz-Lebron and Stephanie Swedik
Levine lab, CWRU

1p SOM W203
Fri, Mar 30
Taussig Institute Grand Rounds
8a CA5-120
Mon, Apr 2
Pathology Research Seminar Series
12p WRB 1-413

Genomic Medicine Institute
Lynn Bekris, PhD
Assistant Staff Genomic Medicine Institute, Cleveland Clinic
"Inflammation related genetic and epigenetic commonalities between Alzheimer's Disease and traumatic brain injury quantitative traits"
12p NE1-205

Cancer Center Research Chalk Talk
1p WRB 3-136

Tumor Immunology and Immunotherapy Meeting
Yong Li PhD
Cancer Biology, Cleveland Clinic
4p WRB 3-136
Tues, Apr 3
Immunology Research Seminar
Sahar Mazhar
Narla Lab, CWRU
"An oncogenic role for PME-1 in lung adenocarcinoma"

12p WRB 1-413

Cancer Biology Seminar 
Aili Zhang, PhD
Research Fellow, Gong Lab, Cancer Biology, Cleveland Clinic
"A novel regulator in DNA damage response" 2p NC1-202 

Cancer Center Research in Progress Seminar
3p WRB 3-136
Thurs, Apr 5
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology Seminar
1p SOM W203
Fri, Apr 6
Taussig Cancer Institute Grand Rounds
8a CA5-120

Cancer Center Seminar Series
Matthew L. Meyerson, MD, PhD
Professor, Pathology, Harvard Medical School;  Professor, Pathology, Medical Oncology, and Director, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute
"Genome alterations in human cancer"
12p WRB 1-413

Case Comprehensive Cancer Center 
11100 Euclid Avenue, Wearn152
Cleveland, OH 44106-5065